Abstract
Carbamazepine is one of the most widely used anticonvulsants in North America; however, its use is associated with a range of serious idiosyncratic adverse reactions. These reactions are thought to result from the formation of chemically reactive metabolites. Carbamazepine is extensively metabolized in the liver and one of the major metabolites is 2-hydroxycarbamazepine, which has previously been detected as a urinary metabolite excreted by rats and humans along with its further metabolized product, 2-hydroxyiminostilbene. In this study, we found that the urine of patients taking carbamazepine appeared to contain more of the glucuronide of 2-hydroxyiminostilbene than that of 2-hydroxycarbamazepine. We have also demonstrated that 2-hydroxyiminostilbene can be oxidized readily to an iminoquinone species by HOCl, H2O2 or even on exposure to air. The reactivity of this iminoquinone as an electrophile was studied. It was shown to react with sulfhydryl-containing nucleophiles, such as glutathione and N-acetylcysteine. We also found a metabolite with the same molecular weight as 4-methylthio-2-hydroxyiminostilbene, but not the corresponding carbamazepine derivative, in the urine of patients taking carbamazepine and this presumably reflects the formation of a glutathione conjugate of the reactive iminoquinone. This iminoquinone intermediate may play a role in carbamazepine-induced idiosyncratic reactions.
Footnotes
-
Send reprint requests to: Chris J. van Koppen, Doctor of Philosophy, Institut für Pharmakologie, Universitätsklinikum Essen, D-45122 Essen, Germany. E-mail:van_koppen{at}uni-essen.de
-
↵1 This work was supported by Grant MT 9336 from the Medical Research Council of Canada.
- Abbreviations:
- TCPO
- trichloropropene oxide
- GSH
- glutathione
- NAC
- N-acetylcysteine
- TIC
- total ion current
- TMS
- trimethylsilyl
- D2O
- deuterium oxide
- MS
- mass spectrometry
- LC
- liquid chromatography
- HPLC
- high-performance liquid chromatography
- TLC
- thin-layer chromatography
- Received March 25, 1998.
- Accepted July 27, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|